National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

PADRE-CMV fusion peptide vaccine
A peptide-based vaccine containing a pan HLA DR-binding epitope (PADRE) fused to a cytomegalovirus (CMV) peptide epitope, with potential anti-viral and immunomodulating activities. Upon administration, PADRE-CMV fusion peptide may stimulate a cytotoxic T-lymphocyte (CTL) response against CMV in the CMV-infected host. The synthetic peptide PADRE is a universal helper T cell epitope. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:paclitaxel poliglumex, paclitaxel vitamin E-based emulsion formulation, paclitaxel-loaded polymeric micelle, padeliporfin, PADRE 965.10
Next:Palestrol, palifermin, palifosfamide, Pallace, palladium Pd 103

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov